The pharmacogenetics of codeine hypoalgesia

Pharmacogenetics

Volumn 5, Issue 6, 1995, Pages 335-346

  Sindrup, Søren H ^a,b   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Codeine; CYP2D6; Hypoalgesia

Indexed keywords

AMITRIPTYLINE; CHLORPROMAZINE; CLOMIPRAMINE; CODEINE; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DESIPRAMINE; DRUG METABOLITE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENZYME INHIBITOR; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LEVOMEPROMAZINE; METOCLOPRAMIDE; MORPHINE; N DEMETHYLASE; NALOXONE; NEUROLEPTIC AGENT; NORCODEINE; NORTRIPTYLINE; O DEMETHYLASE; PAROXETINE; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SPARTEINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ANALGESIA; BIOTRANSFORMATION; CLINICAL TRIAL; DEMETHYLATION; DRUG GLUCURONIDATION; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

ANALGESICS, OPIOID; CODEINE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEBRISOQUIN; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MIXED FUNCTION OXYGENASES; MORPHINE; OXIDATION-REDUCTION; PAIN; PAIN THRESHOLD; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; SPARTEINE;

EID: 0029622428     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199512000-00001     Document Type: Article

References (91)

1. Adler TK, Fujimoto JM, Leong Way E, Baker EM. The metabolic fate of codeine in man. J Pharmacol Exp Ther 1955:114, 251-262.
2. Adler TK. The comparative potencies of codeine and its demethy-lated metabolites after intraventricular injection in the mouse. J Pharmacol Exp Ther 1963: 140, 155-161.
3. Agon P, Braeckman R, van Haver D, Denutte H, Goethals P, Donche H, Vermeullen F, Deman J, Kaufman J-M. Drug disposition in dog brain studied by positron emission tomography. Biophar-maceut Drug Dispos 1988: 9, 567-577.
4. AIvân G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990: 39, 533-537.
5. Arendt-Nielsen L, Nielsen JC, Bjerring P. Double-blind, placebo controlled comparison of paracetamol and paracetamol plus codeine - a quantitative evaluation by laser induced pain. Eur J Clin Pharmacol 1991: 40, 241-247.
6. Barbier. Arch Gen Med 1834: 4. 692.
7. Bechtel WD, Sinterhauf K, Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog. Drug Res 1978: 28, 308-311.
8. Bertilsson L, Alm C, De Las Carreras C, Widen J, Edman G, Schalling D. Debrisoquine hydroxylation polymorphism and personality. Lancet 1989: ii, 555.
9. Brunk SF, Delle M. Morphine metabolism in man. Clin Pharmacol Ther 1975: 16, 51-57.
10. Bresen K, Gram LF. Clinical significance of the sparteine/debriso-quine oxidation polymorphism. Eur J Clin Pharmacol 1989: 36,537-547.
11. Brosen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Invest 1993: 71, 1002-1009.
12. Brosen K, Nielsen PN, Brusgaard K, Gram LF, Skjodt K. CYP2D6 genotype determination in the Danish population. Eur J Clin Pharmacol 1994: 47, 221-225.
13. Cardinale GJ, Donnerer J, Finck AD, Kantrowitz JD, Oka K, Spector S. Morphine and codeine are endogenous components in human cerebrospinal fluid. Life Sci 1987: 40, 301-306.
14. Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet 1988: ii, 914-915.
15. Chen ZR, Irvine RJ, Bochner F, Somogyi AA. Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. Life Sci 1990: 46, 1067-1074.
16. Chen ZR, Somogyi AA, Reynolds G, Bochner F. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br J Clin Pharmacol 1991a: 31, 381-390.
17. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991b: 48, 2165-2171.
18. Cleary J, Mikus G, Somogyi A, Bochner F. The influence of pharmacogenetics on opioid analgesia: Studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. J Pharmacol Exp Ther 1994: 271, 1528-1534.
19. Cooper SA, Engel J, Ladov M, Prêcheur H, Rosenheck A, Rauch D. Analgesie efficacy of an ibuprofen-codeine combination. Pharmacotherapy 1982: 2, 162-167.
20. Dahl E, Feldmann G, Jönsson E. Acetylsalicylic acid compared with acetylsalicylic acid plus codeine as postoperative analgesics after removal of impacted mandibular third molars. Swed Dent J 1985: 9. 207-212.
21. Dahlström B, Tamsen A, Paalzow L, Hartvig P. Patient-controlled analgesic therapy, part IV: pharmacokinetics and analgesic plasma concentrations of morphine. Clin Pharmacokinet 1982: 7. 266-279.
22. Dayer P, Desmeules J, Leemann T, Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufl). Biochem Bio-phys Res Commun 1988: 152,411-416.
23. Dayer P, Desmeules J, Striberni R. In vitro forecasting of drugs that may interfere with codeine bioactivation. Eur J Drug Metabol Pharmacokinet 1992: 17, 115-120.
24. Desmeules J, Gascon M-P, Dayer P, Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991: 41, 23-26.
25. Ebbighausen WOR, Mowat J, Vestergaard P. Mass fragmento-graphic detection of normorphine in urine of man after codeine intake. J Pharm Sci 1973: 62, 146-148.
26. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979: 16, 183-187.
27. Elison C, Elliott HW. N- and O-demethylation of some narcotic analgesics by brain slices from male and female Long-Evans rats. Biochem Pharmacol 1963: 12, 1363-1366.
28. Evans DAB, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980:17, 102-105.
29. Findlay JWA, Butz RF, Welch RM. Codeine kinetics as determined by radioimmunoassay. Clin Pharmacol Ther 1977: 22, 439-446.
30. Findlay JWA, Jones EC, Butz RF, Welch RM. Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. Clin Pharmacol Ther 1978: 24, 60-68.
31. Findlay JWA, Fowle ASE, Butz RF, Jones EC, Weatherley BC, Welch RM, Posner J. Comparative disposition of codeine and pholco-dine in man after single oral doses. Br J Clin Pharmacol 1986: 22, 61-71.
32. Fishman J, Hahn EF, Norton BI. N-demethylation of morphine in rat brain is located in sites with high opiate receptor content. Nature 1976: 261, 64-65.
33. Fonne-Pfister R, Bargetzi MJ, Meyer UA. MPTP, the neurotoxin inducing Parkinson’s disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufl, P450dbl) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 1987: 148, 1144-1150.
34. Forbes JA, Beaver WT, White EH, White RW, Neilson GB, Shackle-ford RW. Diflurrisal: A new oral analgesic with an unusually long duration of action. JAMA 1982: 248, 2139-2142.
35. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debriso-quine/sparteine polymorphism. Am J Hum Gent 1991: 48, 943-950.
36. Giles AD, Pickvance NJ. Combination analgesia following oral surgery. A double-blind comparison of ibuprofen, codeine phosphate and two combination ratios. Clin Trials J 1985: 22, 300-313.
37. Gintzler AR, Mohacsi E, Spector S. Radioimmunoassay for the simultaneous determination of morphine and codeine. Eur J Pharmacol 1976: 38, 149-156.
38. Guay DRP, Awni WM, Halstenson CE, Findlay JWA, Opsahl JA, Abraham PA, Jones EC, Matzke GR. Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers. J Clin Pharmacol 1987: 27, 983-987.
39. Guay DRP, Awni WM, Findlay JWA, Halstenson CE, Abraham PA, Opsahl JA, Jones EC, Matzke GR. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther 1988: 43, 63-71.
40. Happonen R-P, Oksala E, Ylipaavalniemi P. A comparison of acetylsalicylic acid and codeine phosphate versus acetylsali-cylic acid as postoperative analgesics after mandibular third molar surgery. Proc Finn Dent Soc 1987: 83, 32-35.
41. Hasselström J. On the kinetics, metabolism and effects of morphine, codeine and their metabolites. Stockholm: KongI Carolinska Medico Chirurgiska Institutet, 1992.
42. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990: 336, 529-532.
43. Honig S, Murray KA. An appraisal of codeine as an analgesic: single-dose analysis. J Clin Pharmacol 1984: 24, 96-102.
44. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Goodman Gilman A, Rail TW, Nies AS, Taylor P eds. The pharmacological basis of therapeutics. New York: Pergamon Press 1990: 485-521.
45. Jochimsen PR, Noyes R. Appraisal of codeine as an analgesic in older patients. J Am Geriat Soc 1978: 26, 521-523.
46. Johannesson T, Schou J. Morphine and normorphine in the brains of rats given identically analgesic doses of morphine, codeine or normorphine. Acta Pharmacol Toxicol 1963: 20, 165-173.
47. Juan H. Inhibition of the algesic effect of bradykinin and acetylcholine by mepacrine. Naunyn-Schmledeberg’s Arch Pharmacol 1977: 301, 23-27.
48. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 1990: 265, 17209-17214.
49. Kirby GW. Biosynthesis of the morphine alkaloids. Science 1967: 155, 170-172.
50. Kjœrsgaard-Andersen P, Nafei A, Skov O, Madsen F, Andersen HM, Kroner K, Hvass I, Gjoderum O, Pedersen L, Branebjerg PE. Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double-blind, multi-centre study. Pain 1990: 43, 309-318.
51. Kodaira H, Spector S. Transformation of thebaine to oripavine, codeine, and morphine by rat liver, kidney, and brain microsomes. Proc Natl Acad Sci 1988: 85, 1267-1271.
52. Kosterlitz HW. Biosynthesis of morphine in the animal kingdom. Nature 1987: 330, 606.
53. Ladona MG, Lindstrom B, Thyr C, Dun-Ren P, Rane A. Differential foetal development of the 0- and N-demethylation of codeine and dextromethorphan in man. Br J Clin Pharmacol 1991: 32: 295-302.
54. Lee EJD, Moochhala S. Tissue distribution of bufuralol hydroxylase activity in Sprague-Dawley rats. Life Sci 1989: 44, 827-830.
55. Llerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L. Relationship between personality and debrisoquine hydroxyl-ation capacity. Suggestion of an endogenous neuroactive substrate or product of cytochrome P4502D6. Acta Psychiatr Scand 1993: 87, 23-28.
56. Manara L, Bianchetti A. The central and peripheral influences of opioids on gastrointestinal propulsion. Ann Rev Pharmacol Toxicol 1985: 25, 249-273.
57. Martin H. Arch Gen Med 1834: 4, 692.
58. Matsubara K, Fukushima S, Akane A, Kobayashi S, Shiono K. Increased urinary morphine, codeine, and tetrahydropapa veroline in Parkinsonian patient undergoing L-3,4-dihydroxy-phenylalanine therapy: a possible biosynthetic pathway of morphine from L-3,4-dihydroxyphenylalanine in humans. J Pharmacol Exp Ther 1992: 260, 974-978.
59. Mikus G, Somogyi AA, Bochner F, Eichelbaum M. Codeine O-demethylation: rat strain differences and the effects of inhibitors. Biochem Pharmacol 1991: 41, 757-762.
60. Mikus G, Bochner F, Eichelbaum M, Horak P, Somogyi AA, Spector S. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism. J Pharmacol Exp Ther 1994: 268, 546-551.
61. Millan MJ. Multiple opioid systems and pain. Pain 1986: 27, 303-347.
62. Mortimer Ö, Persson K, Ladona MG, Spalding D, Zanger UM, Meyer UA, Rane A. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin Pharmacol Ther 1990: 47, 27-35.
63. Neil A. Morphine- and methadone-tolerant mice differ in cross-tolerance to other opiates: heterogeneity in opioid mechanisms indicated. Naunyn-Schmiedeberg’s Arch Pharmacol 1982: 320, 50-53.
64. Neil A. Affinities of some common opioid analgesics towards four binding sites in mouse brain. Naunyn-Schmiedeberg’s Arch Pharmacol 1984: 328, 24-29.
65. Niznik HB, Tyndale RF, Sallee FR, Gonzales FJ, Hardwick JP, Inaba T, Kalow W. The dopamine transporter and cytochrome P450IID1 (debrisoquine-4-hydroxylase) in brain: resolution and identification of two distinct [5H]GBR-12935 binding proteins. Arch Biochem Biophys 1990: 276, 424-432.
66. Oberst FW. Relationship of the chemical structure of morphine derivatives to their urinary excretion in free and bound forms. J Pharmacol Exp Ther 1941: 73, 401-404.
67. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 1972: 178, 984-986.
68. Persson K, Hammarlund-Udenaes M, Mortimer Ö, Rane A. The postoperative pharmacokinetics of codeine. Eur J Clin Pharmacol 1992: 42, 663-666.
69. Pert CB, Snyder SH. Properties of opiate-receptor binding in rat brain. Proc Natl Acad Sci USA 1973: 70, 2243-2247.
70. Quiding H, Anderson P, Bondesson U, Boréus LO, Hynning P-Â. Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration. Eur J Clin Pharmacol 1986: 30, 673-677.
71. Quiding H, Grimstad J, Rüsten K, Stubhaug A, Bremnes J, Breivik H. Ibuprofen plus codeine, ibuprofen, and placebo in a single- and multidose cross-over comparison for coxarthrosis pain. Pain 1992: 50, 303-307.
72. Quiding H, Lundqvist G, Boréus LO, Bondesson U, Öhrvik J. Analgesic effect and plasma concentrations of codeine and morphine after two dose levels of codeine following oral surgery. Eur J Clin Pharmacol 1993: 44, 319-323.
73. Rafia RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL, Jacoby HI, Selve N. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993: 267, 331-340.
74. Robiquet R. Neue beobachtungen über die vorzüglichsten produkte aus dem opium. Annalen der Pharmacie 1833: 5, 82-111.
75. Rogers JF, Findlay JWA, Hull JH, Butz RF, Jones EC, Bustrack JA, Welch RM. Codeine disposition in smokers and nonsmokers. Clin Pharmacol Ther 1982: 32, 218-227.
76. Sanfilippo G. Contributo sperimentale all’ipotesi della smetilazione della codeina nell’organismo.-I Influenza della dose sull’assuefazione alla codeina.-II Assuefazione alla codeina ottenuta con somministazione prolungata di morfina. Bollettino Società Italiana Biologia Sperimentale 1948: 24, 723-726.
77. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphie dextromethorphan metabolism: cosegregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985: 38, 618-624.
78. Shah JC, Mason WD. Plasma codeine and morphine concentrations after a single oral dose of codeine phosphate. J Clin Pharmacol 1990: 30, 764-766.
79. Sindrup SH, Brosen K, Bjerring P, Arendt-Nielsen L, Larsen U, Angelo HR, Gram LF. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 1990: 48, 686-693.
80. Sindrup SH, Arendt-Nielsen L, Brosen K, Bjerring P, Angelo HR, Eriksen B, Gram LF. The effect of quinidine on the analgesic effect of codeine. Eur J Clin Pharmacol 1992: 42, 587-592.
81. Sindrup SH, Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain 1993: 53, 335-349.
82. Sindrup SH, Hofmann U, Asmussen J, Mikus G, Brosen K, Nielsen F, Ingwersen SH, Christensen CB. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake (in press 1995).
83. Somogyi AA, Kerry N, Cleary J, Mikus G, Gyldenvang L, Bochner F. Codeine-induced analgesia is via morphine formation: evidence from in vitro and in vivo animal and human studies. Seattle: IASP Publications, 1993: 533.
84. Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzales FJ, Niznik HB. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): Potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991: 40, 63-68.
85. Wallenstein SL, Houde RW, Bellwille JW. Relative potency and effectiveness of codeine and morphine. Fed Proc 19 61:20, 311.
86. Wallenstein SL, Houde RW, Beaver WT. Analgesic studies of orally and parentally administered morphine and codeine in patients with cancer. Fed Proc 1967: 26, 742.
87. Yue QY, Svensson J-O, Alm C, Sjöqvist F, Säwe J. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol 1989a: 28, 639-645.
88. Yue QY, Svensson J-O, Alm C, Sjöqvist F, Säwe J. Interindividual and interethnic differences in the demethylation and glucuronida-tion of codeine. Br J Clin Pharmacol 1989b: 28, 629-637.
89. Yue QY, Hasselström J, Svensson J-O, Säwe J. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1991: 31, 635-642.
90. Yue QY, Tomson T, Säwe J. Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man. Pharmacogenetics 1994: 4, 193-198.
91. Zanger UM, Vilbois F, Hardwick JP, Meyer UA. Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988: 27, 5447-5454.